The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
The closing price of ImmunityBio Inc (NASDAQ: IBRX) was $4.94 for the day, down -6.26% from the previous closing price of $5.27. In other words, the price has decreased by $-6.26 from its previous closing price. On the day, 4.24 million shares were traded. IBRX stock price reached its highest trading level at $5.3482 during the session, while it also had its lowest trading level at $4.92.
Ratios:
Our analysis of IBRX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 5.05 and its Current Ratio is at 5.05.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Piper Sandler on May 12, 2023, Downgraded its rating to Neutral and sets its target price to $4 from $10 previously.
On August 03, 2022, Jefferies started tracking the stock assigning a Buy rating and target price of $8.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jun 05 ’23 when BLASZYK MICHAEL D bought 71,915 shares for $2.75 per share. The transaction valued at 198,023 led to the insider holds 71,915 shares of the business.
Brennan John Owen bought 25,000 shares of IBRX for $70,700 on Jun 02 ’23. The Director now owns 25,000 shares after completing the transaction at $2.83 per share. On Jun 01 ’23, another insider, Clark Wesley, who serves as the Director of the company, bought 7,000 shares for $2.91 each. As a result, the insider paid 20,370 and bolstered with 8,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IBRX now has a Market Capitalization of 3344395008 and an Enterprise Value of 4169993472. For the stock, the TTM Price-to-Sale (P/S) ratio is 5369.86. Its current Enterprise Value per Revenue stands at 6704.17 whereas that against EBITDA is -12.163.
Stock Price History:
The Beta on a monthly basis for IBRX is 1.17, which has changed by 1.159836 over the last 52 weeks, in comparison to a change of 0.2006725 over the same period for the S&P500. Over the past 52 weeks, IBRX has reached a high of $6.93, while it has fallen to a 52-week low of $1.25. The 50-Day Moving Average of the stock is -3.80%, while the 200-Day Moving Average is calculated to be 45.82%.
Shares Statistics:
IBRX traded an average of 4.20M shares per day over the past three months and 4073480 shares per day over the past ten days. A total of 670.87M shares are outstanding, with a floating share count of 136.93M. Insiders hold about 79.68% of the company’s shares, while institutions hold 8.49% stake in the company. Shares short for IBRX as of 1711584000 were 54765227 with a Short Ratio of 13.03, compared to 1709164800 on 51547481. Therefore, it implies a Short% of Shares Outstanding of 54765227 and a Short% of Float of 38.970003.
Earnings Estimates
Current recommendations for the stock of the company come from ImmunityBio, Inc. analysts. The consensus estimate for the next quarter is $1.37, with high estimates of $41.87 and low estimates of $4.30.
